The aim of the iPDM-GO project is to improve diabetes care applying the "integrated Personalised Diabetes Management" (iPDM) in Denmark. The goal is to enhance the iPDM approach with innovative personalized health technology and implement outcomes-based healthcare payment. The ultimate goal is to encourage individualised treatment of diabetes, as well as deploy a payment systems that reward better healthcare, throughout Europe.
Diabetes mellitus provides a huge and multidimensional challenge for European societies. In 2017, the International Diabetes Federation (IDF) estimated that there were approximately 425 million people with diabetes around the world with numbers continuing to rise. As a consequence, the costs of diabetes care are also continuously rising and becoming more and more of a global challenge. It is thus key to provide cost-effective health services that are tailored to each patient’s unique needs and requirements.
Integrated Personalized Diabetes Management (iPDM), strives to address this problem. It is a therapeutic approach which structures the treatment process, connects HCPs and patients, and integrates digital tools that visualize and analyze data. The PDM ProValue study program demonstrates the success of the programme. Patients who were treated for twelve months according to a pre-defined iPDM process achieved significantly better outcomes compared to a control group treated with usual care.
Objectives
Integrated Personalised Diabetes Management Goes Europe (iPDM-GO) intends to test iPDM in a Danish community setting. The vision of the multi-disciplinary consortium of partners from industry, academia and healthcare administration in Germany and Denmark is to develop and implement a digitally enabled, person-centered care process for people with type 2 diabetes focusing on improving outcomes that matter to patients, and contributing to the sustainability of healthcare systems. Collectively, the team has extensive expertise and skills in clinical practice, computer science, health psychology, health economics, bioinformatics and close-to-market clinical research and development.
An important part of the project – and the main responsibility of CACHET – is to design a personalized patient-assessment healthcare technology tool that can capture the unique needs, circumstances and challenges of each person with diabetes, in order to identify the most appropriate solutions and services. This technology will explore new opportunities for leveraging Big Data analysis and deliver effective educational programmes to patients.
Figure 1 – co-creation of a digital patient assessment tool.
To support the transformation of healthcare from volume-based to value-based, iPDM-GO will develop a healthcare transformation toolkit that guides the implementation of outcomes-based care in European countries.
Impact
iPDM-GO is seeking to make a positive impact on:
- People with diabetes, by delivering personalised solutions and services that improve their ability to manage their disease, and enhance their quality of life.
- People with chronic diseases, by promoting results-oriented healthcare.
- Healthcare systems and payers, by prioritising good results from healthcare services.
About EIT Health
iPDM-GO is funded by EIT Health as an Innovation Project. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union that receives support from the European Union´s Horizon Europe Research and innovation programme.